These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 24375427)

  • 1. Design of lipid matrix particles for fenofibrate: effect of polymorphism of glycerol monostearate on drug incorporation and release.
    Xia D; Cui F; Gan Y; Mu H; Yang M
    J Pharm Sci; 2014 Feb; 103(2):697-705. PubMed ID: 24375427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigating the correlation between in vivo absorption and in vitro release of fenofibrate from lipid matrix particles in biorelevant medium.
    Borkar N; Xia D; Holm R; Gan Y; Müllertz A; Yang M; Mu H
    Eur J Pharm Sci; 2014 Jan; 51():204-10. PubMed ID: 24134899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved dissolution rate and bioavailability of fenofibrate pellets prepared by wet-milled-drug layering.
    Wang P; Luo Q; Miao Y; Ying L; He H; Cai C; Tang X
    Drug Dev Ind Pharm; 2012 Nov; 38(11):1344-53. PubMed ID: 22283480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poly(vinyl alcohol) as emulsifier stabilizes solid triglyceride drug carrier nanoparticles in the alpha-modification.
    Rosenblatt KM; Bunjes H
    Mol Pharm; 2009; 6(1):105-20. PubMed ID: 19049318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preparation and in vitro/in vivo evaluation of fenofibrate nanocrystals.
    Zuo B; Sun Y; Li H; Liu X; Zhai Y; Sun J; He Z
    Int J Pharm; 2013 Oct; 455(1-2):267-75. PubMed ID: 23876497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancing the Solubility of Fenofibrate by Nanocrystal Formation and Encapsulation.
    Kumar R; Siril PF
    AAPS PharmSciTech; 2018 Jan; 19(1):284-292. PubMed ID: 28702816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polyhydroxy surfactants for the formulation of lipid nanoparticles (SLN and NLC): effects on size, physical stability and particle matrix structure.
    Kovacevic A; Savic S; Vuleta G; Müller RH; Keck CM
    Int J Pharm; 2011 Mar; 406(1-2):163-72. PubMed ID: 21219990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation and characterization of silybin-loaded nanostructured lipid carriers.
    Jia LJ; Zhang DR; Li ZY; Feng FF; Wang YC; Dai WT; Duan CX; Zhang Q
    Drug Deliv; 2010 Jan; 17(1):11-8. PubMed ID: 19941406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Solid lipid nanodispersions containing mixed lipid core and a polar heterolipid: characterization.
    Attama AA; Schicke BC; Paepenmüller T; Müller-Goymann CC
    Eur J Pharm Biopharm; 2007 Aug; 67(1):48-57. PubMed ID: 17276663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous and scalable process for water-redispersible nanoformulation of poorly aqueous soluble APIs by antisolvent precipitation and spray-drying.
    Hu J; Ng WK; Dong Y; Shen S; Tan RB
    Int J Pharm; 2011 Feb; 404(1-2):198-204. PubMed ID: 21056643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dissolution-rate enhancement of fenofibrate by adsorption onto silica using supercritical carbon dioxide.
    Sanganwar GP; Gupta RB
    Int J Pharm; 2008 Aug; 360(1-2):213-8. PubMed ID: 18550302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Solid self-emulsifying drug delivery system (S-SEDDS) for improved dissolution rate of fenofibrate.
    Kanaujia P; Ng WK; Tan RB
    J Microencapsul; 2014; 31(3):293-8. PubMed ID: 24156747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral Nanoemulsion of Fenofibrate: Formulation, Characterization, and
    Gulati N; Kumar Chellappan D; Tambuwala M; A A Aljabali A; Prasher P; Kumar Singh S; Anand K; Sharma A; Kumar Jha N; Gupta G; Dua K; Dureja H
    Assay Drug Dev Technol; 2021; 19(4):246-261. PubMed ID: 33989048
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug-Lipid-Surfactant Miscibility for the Development of Solid Lipid Nanoparticles.
    Trivino A; Gumireddy A; Chauhan H
    AAPS PharmSciTech; 2019 Jan; 20(2):46. PubMed ID: 30617602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High drug load, stable, manufacturable and bioavailable fenofibrate formulations in mesoporous silica: a comparison of spray drying versus solvent impregnation methods.
    Hong S; Shen S; Tan DC; Ng WK; Liu X; Chia LS; Irwan AW; Tan R; Nowak SA; Marsh K; Gokhale R
    Drug Deliv; 2016; 23(1):316-27. PubMed ID: 24853963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of a fenofibrate-hydroxypropyl-beta-cyclodextrin system prepared by a co-grinding method.
    Gu FG; Wang Y; Meng GD; Han HB; Wu CZ
    Pharmazie; 2012 Feb; 67(2):143-6. PubMed ID: 22512084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of particle preparation methods and polymorphic stability of lipid excipients on protein distribution in microparticles.
    Liu J; Christophersen PC; Yang M; Nielsen HM; Mu H
    Drug Dev Ind Pharm; 2017 Dec; 43(12):2032-2042. PubMed ID: 28756687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigating the effect of moisture protection on solid-state stability and dissolution of fenofibrate and ketoconazole solid dispersions using PXRD, HSDSC and Raman microscopy.
    Kanaujia P; Lau G; Ng WK; Widjaja E; Schreyer M; Hanefeld A; Fischbach M; Saal C; Maio M; Tan RB
    Drug Dev Ind Pharm; 2011 Sep; 37(9):1026-35. PubMed ID: 21417604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aminoclay-lipid hybrid composite as a novel drug carrier of fenofibrate for the enhancement of drug release and oral absorption.
    Yang L; Shao Y; Han HK
    Int J Nanomedicine; 2016; 11():1067-76. PubMed ID: 27042061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies on binary lipid matrix based solid lipid nanoparticles of repaglinide: in vitro and in vivo evaluation.
    Rawat MK; Jain A; Singh S
    J Pharm Sci; 2011 Jun; 100(6):2366-78. PubMed ID: 21491449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.